A phase II open-label randomized clinical trial of preoperative durvalumab or durvalumab plus tremelimumab in resectable head and neck squamous cell carcinoma
Clin. Cancer Res., Mar 08 2024, | https://doi.org/10.1158/1078-0432.CCR-23-3249
Trastuzumab combined with ramucirumab and paclitaxel in patients with previously treated human epidermal growth factor receptor 2–positive advanced gastric or gastroesophageal junction cancer
J. Clin. Oncol., Published online June 26, 2023 | DOI: 10.1200/JCO.22.02122